



**INTERNATIONAL JOURNAL OF
PHARMACEUTICAL SCIENCES**
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: <https://www.ijpsjournal.com>



Review Article

Pharmaceutical Quality Assurance: Principles, Regulatory Framework, Current Practices and Emerging Trends – A Review

Santosh Kumar^{1*}, Kusum Bala²

¹ Pataudi College of Pharmacy, Pataudi, Gurugram, Haryana, India.

² All Saints International School, Tapukara, Bhiwadi, Rajasthan, India.

ARTICLE INFO

Published: 28 Oct 2026

Keywords:

data integrity, pharmaceutical quality assurance, pharmaceutical quality system, quality by design, quality risk management, validation

DOI:

10.5281/zenodo.23727721

ABSTRACT

Pharmaceutical quality assurance (QA) is a comprehensive and systematic approach designed to ensure that medicinal products consistently meet predetermined standards of quality, safety, identity, strength, purity and efficacy throughout their intended life-cycle. The contemporary pharmaceutical industry has moved beyond a predominantly end-product testing model toward integrated, science-based and risk-based quality management. Good Manufacturing Practices (GMP), Pharmaceutical Quality Systems (PQS), Quality Risk Management (QRM), Quality by Design (QbD), validation, qualification, change control, deviation management, corrective and preventive action (CAPA), supplier qualification, documentation and data integrity constitute major components of modern pharmaceutical QA. International regulatory frameworks developed by the World Health Organization (WHO), International Council for Harmonisation (ICH), United States Food and Drug Administration (FDA) and other regulatory bodies increasingly emphasize lifecycle management, continual improvement and reliable data. The 2024 tenth edition of the WHO pharmaceutical quality assurance compendium provides an updated global framework extending from pharmaceutical development and manufacturing to quality control and post-marketing surveillance. Recent advances in digitalization, artificial intelligence (AI), machine learning (ML), Process Analytical Technology (PAT), continuous manufacturing and advanced data analytics are further transforming pharmaceutical quality management. However, these technologies also introduce challenges related to validation, data integrity, cyber security, model governance and regulatory acceptance. This review discusses the fundamental concepts, major components, regulatory framework, implementation strategies, current challenges and emerging trends in pharmaceutical quality assurance.

***Corresponding Author:** Santosh Kumar

Address: Pataudi College of Pharmacy, Pataudi, Gurugram, Haryana, India

Email ✉: santoshpatodia82@gmail.com

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.



An integrated lifecycle-based QA system supported by scientific understanding, risk management, robust documentation, quality culture and appropriate technology is essential for ensuring consistent product quality and protecting patient safety.

INTRODUCTION

Medicinal products are expected to meet predefined quality standards throughout their intended shelf life. The quality of a pharmaceutical product is closely associated with its identity, strength, purity, stability, safety and therapeutic performance. Because patients generally cannot independently verify the quality of a medicine before administration, pharmaceutical manufacturers and regulatory authorities have a fundamental responsibility to establish systems that minimize quality-related risks.

Pharmaceutical quality assurance is broader than quality control testing of finished products. It encompasses the organizational arrangements, procedures, resources and systematic activities required to provide confidence that a pharmaceutical product will consistently meet established quality requirements. The WHO pharmaceutical quality assurance framework covers activities extending from development and manufacturing to quality control and post-marketing surveillance. The tenth edition of the WHO compendium, published in 2024, was specifically developed to reflect the increasing complexity of pharmaceutical product lifecycles and the changing global regulatory environment.^{1,2}

The pharmaceutical industry has progressively shifted from an inspection-based approach toward a preventive and science-based quality model. In this approach, quality is designed into the product and process rather than being dependent exclusively on final-product testing. Quality by Design, quality risk management and pharmaceutical quality systems have therefore become important elements of contemporary pharmaceutical development and manufacturing. Recent literature also emphasizes the role of QbD in improving process understanding, product robustness and regulatory compliance.³⁻⁵

The globalization of pharmaceutical supply chains has further increased the importance of harmonized quality

standards. ICH quality guidelines currently include Q8 Pharmaceutical Development, Q9 Quality Risk Management, Q10 Pharmaceutical Quality System, Q12 Product Lifecycle Management, Q13 Continuous Manufacturing and Q14 Analytical Procedure Development.⁶

This review summarizes the major principles and practices of pharmaceutical QA and discusses the transition toward lifecycle-based, risk-based and digitally enabled quality management.

MATERIALS AND METHODS

This narrative review was developed using authoritative regulatory and scientific sources relevant to pharmaceutical quality assurance. The principal regulatory sources included the World Health Organization (WHO) Quality Assurance of Pharmaceuticals compendium, International Council for Harmonisation (ICH) quality guidelines, and U.S. Food and Drug Administration (FDA) pharmaceutical quality resources. Recent peer-reviewed literature was used to support discussion of Quality by Design, data integrity, continuous manufacturing, artificial intelligence and Industry 4.0. Emphasis was placed on lifecycle-based quality management, risk management, regulatory expectations, current implementation challenges and emerging technologies. The review is narrative in nature and was not designed as a systematic review or meta-analysis.

RESULTS AND DISCUSSION

3.1. Evolution of Pharmaceutical Quality Assurance

The evolution of pharmaceutical quality assurance can broadly be considered in four stages.

3.1.1. Inspection and testing-oriented approach

Early pharmaceutical quality systems relied heavily on inspection and laboratory testing of finished products. This approach could detect nonconforming products but had limited ability to prevent process-related failures.

3.1.2. GMP-oriented approach

The development and implementation of GMP established requirements for manufacturing premises,



equipment, personnel, documentation, sanitation, production, quality control and distribution.

3.1.3. Quality-system approach

Modern pharmaceutical organizations increasingly integrated GMP activities into broader pharmaceutical quality systems. Quality risk management, CAPA,

change control, management review and continual improvement became interconnected components.

3.1.4. Lifecycle and digital quality approach

The contemporary model emphasizes product and process knowledge throughout the lifecycle, risk-based decision-making, data integrity, QbD, PAT, continuous manufacturing and digital quality management.

Table 1: Major Components of Pharmaceutical Quality Assurance

Component	Primary purpose
GMP	Consistent compliant manufacturing
Quality Management System	Organization-wide quality framework
Quality Risk Management	Identification and control of risks
Validation	Demonstration of consistent process/system performance
Qualification	Confirmation of equipment/facility suitability
Documentation	Evidence and traceability
Data Integrity	Reliability and completeness of data
CAPA	Correction and prevention of quality problems
Change Control	Controlled implementation of changes
Supplier Qualification	Control of external quality risks
Auditing	Independent evaluation of systems
Product Quality Review	Periodic assessment of product/process performance

WHO's 2024 QA compendium illustrates this broader lifecycle perspective by integrating guidance covering development, manufacturing, quality control and post-marketing activities.^{1,2}

3.2. Objectives of Pharmaceutical Quality Assurance

The major objectives of pharmaceutical QA include:

1. Ensuring consistent product quality.
2. Protecting patients from unsafe or defective medicines.
3. Preventing contamination and cross-contamination.
4. Ensuring compliance with applicable regulatory requirements.
5. Establishing controlled and reproducible manufacturing processes.
6. Ensuring reliable documentation and data integrity.
7. Identifying and controlling quality risks.
8. Preventing recurrence of quality-related failures.

9. Maintaining product quality throughout the lifecycle.

10. Promoting continual improvement and a strong quality culture.

QA therefore represents a proactive organizational system rather than a single department or laboratory activity.

3.3. Pharmaceutical Quality Assurance versus Quality Control

Quality assurance and quality control are complementary but conceptually different.

Quality Assurance (QA) is predominantly system-oriented and preventive. It establishes and maintains the systems necessary to ensure that processes are appropriately designed, controlled, documented and reviewed.

Quality Control (QC) is primarily concerned with sampling, specifications, analytical testing and assessment of whether materials and products meet established requirements.



Table 2: Comparison of Quality Assurance and Quality Control

Parameter	Quality Assurance	Quality Control
Primary orientation	Preventive/system-oriented	Testing/detection-oriented
Main objective	Ensure quality through controlled systems	Verify compliance with specifications
Major activities	GMP, validation, audits, CAPA, change control	Sampling and laboratory testing
Focus	Processes and quality systems	Materials and products
Timing	Throughout lifecycle	Mainly during defined testing stages
Documentation	SOPs, protocols, deviations, CAPA, audits	Test records and analytical reports
Responsibility	Organization-wide	Primarily QC function
Approach	Proactive	Primarily analytical/detective

Effective pharmaceutical quality depends on integration between QA and QC rather than treating them as isolated functions.

3.4. Good Manufacturing Practices as the Foundation of QA

Good Manufacturing Practices are one of the principal foundations of pharmaceutical quality assurance. WHO's GMP framework addresses manufacturing and quality-control activities intended to ensure the quality, safety and efficacy of pharmaceutical products.^{2,7,8}

Important GMP areas include:

- Pharmaceutical quality systems
- Personnel
- Premises and facilities
- Equipment
- Sanitation and hygiene
- Production
- Packaging and labeling
- Quality control
- Documentation
- Qualification and validation
- Complaints
- Product recalls
- Self-inspection
- Supplier management

The 2024 WHO GMP compendium incorporates updated guidance for areas including quality management systems, validation, data integrity, technology transfer,

storage and distribution, sterile products and other specialized manufacturing areas.²

GMP should therefore be viewed as an integrated system of controls designed to minimize risks that could adversely affect product quality.

3.5. Pharmaceutical Quality System

The Pharmaceutical Quality System (PQS) provides an organizational framework for managing pharmaceutical quality.

Table 3: Conventional Versus Modern Pharmaceutical QA

Conventional approach	Modern approach
End-product testing	Quality built into process
Reactive	Preventive and predictive
Batch-focused	Lifecycle-focused
Fixed processes	Continual improvement
Limited process understanding	Science-based process understanding
Manual documentation	Digital quality systems
Periodic testing	Increasing real-time monitoring
Compliance-oriented	Risk- and knowledge-oriented
Human-only data review	Data analytics and AI-assisted review
Quality department-centered	Organization-wide quality culture

ICH Q10 describes a lifecycle-based pharmaceutical quality system extending from pharmaceutical development through technology transfer, commercial manufacturing and product discontinuation.⁹ Major elements include:

- Process performance and product quality monitoring



- CAPA
- Change management
- Management review
- Knowledge management
- Quality risk management

The effectiveness of a PQS depends not only on documented procedures but also on leadership commitment, employee involvement, appropriate resources and an organizational culture that prioritizes quality.

FDA's Quality Management Maturity (QMM) initiative illustrates the increasing regulatory interest in quality systems that go beyond minimum CGMP compliance and support continual improvement, quality culture and supply reliability.¹⁸

3.6. Quality Risk Management

Quality Risk Management (QRM) provides a structured framework for identifying, assessing, controlling, communicating and reviewing risks to pharmaceutical quality.

ICH Q9 (R1) provides the principal international framework for pharmaceutical QRM.¹⁰

Risk-management cycle

Risk identification → Risk analysis → Risk evaluation → Risk control → Risk communication → Risk review

Commonly used tools include:

- Failure Mode and Effects Analysis (FMEA)
- Fault Tree Analysis (FTA)
- Hazard Analysis and Critical Control Points (HACCP)
- Hazard Operability Analysis (HAZOP)
- Risk ranking and filtering
- Ishikawa/fishbone analysis

Risk management should be science-based and proportionate to the potential impact of the identified risk.

A mature QRM system should not be limited to individual deviations. It should support decisions concerning product development, suppliers, process validation,

change control, cleaning, contamination control, computerized systems and lifecycle management.

3.7. Quality by Design

Quality by Design represents a systematic and science-based approach to pharmaceutical development.^{5,11}

The major QbD elements include:

- Quality Target Product Profile (QTPP)
- Critical Quality Attributes (CQAs)
- Critical Material Attributes (CMAs)
- Critical Process Parameters (CPPs)
- Risk assessment
- Design of Experiments (DoE)
- Design space
- Control strategy
- Continued process verification

QbD aims to establish a scientifically justified understanding of the relationships between formulation variables, material properties, process parameters and product quality.

Recent reviews indicate that QbD can improve process understanding, product robustness and regulatory flexibility, although implementation in routine commercial manufacturing remains variable.³⁻⁵

The continuing development of QbD has also expanded toward biologics, advanced therapies, complex formulations and personalized medicine.¹²

3.8. Validation and Qualification

Validation provides documented evidence that a process, method, system or procedure can consistently achieve predefined requirements.¹³

Major validation activities include:

3.8.1. Process validation

Demonstrates that a manufacturing process can consistently produce product meeting predefined quality requirements.

3.8.2. Cleaning validation

Demonstrates that cleaning procedures effectively control residues and contaminants.



3.8.3. Analytical method validation

Demonstrates that an analytical procedure is suitable for its intended purpose.

3.8.4. Computerized system validation

Ensures that computerized systems used in regulated activities operate reliably and maintain data integrity.

3.8.5. Equipment qualification

Typically includes:

DQ → IQ → OQ → PQ

Where:

- DQ = Design Qualification
- IQ = Installation Qualification
- OQ = Operational Qualification
- PQ = Performance Qualification

Validation should be viewed as a lifecycle activity rather than a one-time exercise.

3.9. Documentation and Good Documentation Practices

Documentation provides objective evidence that pharmaceutical operations have been performed according to approved procedures.

Important documents include:

- Standard Operating Procedures
- Batch Manufacturing Records
- Batch Packaging Records
- Specifications
- Analytical methods
- Validation protocols
- Validation reports
- Equipment qualification documents
- Training records
- Deviation reports
- CAPA records
- Change-control records
- Audit reports

- Product Quality Reviews

A fundamental principle of pharmaceutical documentation is that activities should be documented contemporaneously, accurately and in a manner that permits reconstruction of events.¹⁴

Poor documentation can compromise the ability to establish whether a product was manufactured and tested appropriately.

3.10. Data Integrity

Data integrity has become one of the most important components of contemporary pharmaceutical QA.^{15,16}

Data should be complete, consistent, accurate, attributable, legible and appropriately recorded throughout its lifecycle.

The commonly used ALCOA principles require data to be:

- Attributable
- Legible
- Contemporaneous
- Original
- Accurate

Electronic systems additionally require appropriate controls over:

- User access
- Audit trails
- Electronic signatures
- Data backup
- System security
- Change management
- Data review

A review of pharmaceutical data-integrity problems identified organizational culture, leadership, processes, technology and individual behavior among important contributing factors.^{15,16}

Data integrity should therefore be integrated into the overall PQS rather than treated as a separate IT issue.

3.11. Deviation Management



A deviation represents a departure from an approved procedure, specification, process or established requirement.

A robust deviation-management process generally includes:

1. Deviation identification
2. Immediate containment
3. Preliminary assessment
4. Investigation
5. Root-cause analysis
6. Product/process impact assessment
7. CAPA development
8. Effectiveness verification
9. QA review
10. Closure

Common root-cause tools include:

- Five Whys
- Fishbone analysis
- FMEA
- Fault Tree Analysis
- Pareto analysis

The objective should be to identify and address the underlying systemic cause rather than simply correcting the immediate problem.

3.12. Corrective and Preventive Action

CAPA is a core element of pharmaceutical quality systems.

Corrective action

Corrective action addresses the cause of an identified nonconformity or problem.

Preventive action

Preventive action aims to prevent potential recurrence or occurrence of quality problems.

An effective CAPA system should include:

Problem identification → Root cause → Corrective action → Preventive action → Implementation → Effectiveness check

Repeated deviations of similar nature should trigger trend analysis and assessment of whether the existing CAPA system is effective.

3.13. Change Control

Pharmaceutical manufacturing processes are subject to changes involving:

- Raw materials
- Suppliers
- Equipment
- Facilities
- Manufacturing processes
- Analytical methods
- Packaging
- Computerized systems
- Specifications
- Documents

Uncontrolled changes can adversely affect product quality.

A typical change-control process is:

Change proposal → Risk assessment → Impact assessment → QA approval → Implementation → Verification → Closure

The degree of assessment should correspond to the potential impact of the change on product quality and regulatory commitments.

ICH Q10 and Q12 provide an important foundation for lifecycle management and controlled change.^{6,9,17}

Table 4: Important ICH Quality Guidelines Relevant to Pharmaceutical QA

Guideline	Major area
ICH Q1	Stability
ICH Q2(R2)	Analytical procedure validation
ICH Q3	Impurities
ICH Q6	Specifications
ICH Q7	GMP for APIs
ICH Q8(R2)	Pharmaceutical development/QbD
ICH Q9(R1)	Quality Risk Management



Guideline	Major area
ICH Q10	Pharmaceutical Quality System
ICH Q11	Drug substance development/manufacture
ICH Q12	Product lifecycle management
ICH Q13	Continuous manufacturing
ICH Q14	Analytical procedure development

3.14. Supplier Qualification and Supply-Chain Quality

Modern pharmaceutical manufacturing depends on complex global supply chains involving API manufacturers, excipient suppliers, packaging suppliers, contract manufacturers, testing laboratories and logistics providers.

Supplier quality management should include:

- Initial supplier assessment
- Supplier qualification
- Quality agreements
- Supplier audits where appropriate
- Material specifications
- Certificate-of-analysis review
- Incoming-material controls
- Supplier performance monitoring
- Periodic reassessment

Supply-chain quality is particularly important because quality failures can originate outside the final manufacturing facility.

FDA's QMM initiative recognizes the relationship between mature quality management and reliable pharmaceutical supply, while FDA's annual State of Pharmaceutical Quality report provides surveillance data on manufacturers, products and post-market quality defects.^{18,19}

3.15. Quality Control Laboratory and Analytical Quality

The QC laboratory provides analytical evidence concerning the quality of pharmaceutical materials and products.

Major laboratory activities include:

- Sampling
- Identification testing
- Assay
- Impurity testing
- Dissolution
- Uniformity testing
- Microbiological testing
- Stability testing
- Environmental monitoring where applicable

WHO's 2024 good-practice guidance for pharmaceutical QC laboratories is aligned with GMP requirements and ISO/IEC 17025 principles.²⁰

Analytical procedures must be appropriately developed, qualified or validated and controlled throughout their lifecycle.²¹

3.16. Audits and Regulatory Inspections

Auditing is an important mechanism for evaluating the effectiveness of quality systems.

Types of audits

- Internal audits
- Supplier audits
- Contract-manufacturer audits
- Quality-system audits
- Regulatory inspections
- Mock inspections

An effective audit system should identify systemic weaknesses and generate meaningful CAPA rather than simply producing a list of observations.

Regulatory authorities use inspections and other quality-surveillance mechanisms to evaluate pharmaceutical manufacturing and product quality. FDA's annual State of Pharmaceutical Quality reporting also provides a broader surveillance perspective on manufacturers, products and post-market quality defects.¹⁹

3.17. Process Analytical Technology



Process Analytical Technology (PAT) is an important component of advanced pharmaceutical manufacturing.

PAT can involve:

- Near-infrared spectroscopy
- Raman spectroscopy
- Infrared spectroscopy
- In-line sensors
- At-line testing
- Multivariate statistical analysis
- Real-time process monitoring

The fundamental concept is to understand and control manufacturing processes in real time rather than relying solely on testing after production.

Recent literature on continuous manufacturing highlights the potential of NIR and Raman spectroscopy for real-time process assessment and quality assurance.^{22,23}

3.18. Continuous Manufacturing

Traditional pharmaceutical manufacturing commonly uses discrete batch operations. Continuous manufacturing integrates multiple processing steps into a connected production process.

Potential benefits include:

- Improved process control
- Reduced process variability
- Increased automation
- Smaller manufacturing footprint
- Faster processing
- Real-time monitoring
- Potential improvement in supply flexibility

ICH Q13 provides an international framework for continuous manufacturing of drug substances and drug products.²³

Successful implementation requires appropriate process understanding, control strategy, PAT, material traceability, equipment integration and regulatory oversight.

3.19. Artificial Intelligence and Machine Learning in Pharmaceutical QA

Artificial intelligence and machine learning are increasingly being investigated across pharmaceutical development, manufacturing and quality management.

Potential QA applications include:

- Deviation trend analysis
- Predictive maintenance
- Anomaly detection
- Batch-performance prediction
- Process monitoring
- Automated document review
- Quality-risk prediction
- Supplier-risk analysis
- Analytical data interpretation
- Predictive quality control

A 2024 review reported expanding applications of AI and ML across pharmaceutical development, manufacturing and quality control/assurance.^{12,24}

Table 5: Potential Applications of AI/ml in Pharmaceutical QA

Application	Potential use
Deviation analysis	Identification of recurring patterns
Predictive maintenance	Prediction of equipment failure
Process monitoring	Detection of abnormal process behavior
Quality prediction	Prediction of critical quality outcomes
Document review	Automated identification of inconsistencies
Supplier risk	Risk-based supplier monitoring
Trend analysis	Detection of emerging quality signals
QC data analysis	Pattern recognition and anomaly detection
CAPA support	Identification of recurring root-cause patterns

However, AI-based QA systems require careful attention to:



- Data quality
- Model validation
- Model drift
- Explainability
- Cyber security
- Access control
- Human oversight
- Regulatory acceptability

AI should therefore augment, rather than eliminate, appropriately qualified human decision-making in regulated pharmaceutical operations.

3.20. Pharmaceutical Quality Management and Industry 4.0

Industry 4.0 technologies are changing pharmaceutical quality management through increased connectivity and automation.

Important technologies include:

- Internet of Things (IoT)
- Cloud computing
- AI/ML
- Big-data analytics
- Digital twins
- Electronic batch records
- Manufacturing Execution Systems
- Laboratory Information Management Systems
- Electronic Quality Management Systems

The integration of these systems can improve data availability and process visibility but can also increase the complexity of validation and cyber security.

Data integrity therefore remains a central requirement of digital pharmaceutical QA.^{15,16,25}

3.21. Quality Management Maturity

An important recent development is the movement from basic regulatory compliance toward quality management maturity.

FDA's QMM program seeks to encourage manufacturers to implement quality-management practices that go

beyond minimum CGMP requirements. The program emphasizes quality culture, continual improvement, identification of opportunities for enhancement and reliable supply.^{18,19}

Quality maturity can involve:

- Strong leadership commitment
- Employee engagement
- Proactive risk management
- Data-driven decision-making
- Effective knowledge management
- Process capability monitoring
- Continual improvement
- Supply-chain resilience

This represents a shift from asking only “Are we compliant?” toward also asking “How robust and mature is our quality system?”

3.22. Emerging Trends

Pharmaceutical quality assurance is increasingly evolving from a predominantly compliance-driven function toward a proactive, data-driven and lifecycle-based approach. Emerging technologies and quality-management strategies are supporting improved process understanding, earlier identification of quality risks and continual improvement across the pharmaceutical product lifecycle.

Digitalization is becoming an important component of pharmaceutical quality management. Electronic quality-management systems, electronic batch records, laboratory information systems, manufacturing execution systems and advanced data analytics can improve traceability, data availability and process visibility. However, their implementation requires appropriate computerized-system validation, data-integrity controls, cyber security and access management.^{15,16,25}

Artificial intelligence (AI) and machine learning (ML) are emerging as potential tools for deviation analysis, anomaly detection, predictive maintenance, process monitoring, quality-risk assessment and automated review of quality-related information. Their application in regulated pharmaceutical environments requires attention to data quality, model validation,



explainability, model drift, cyber security and human oversight.^{12,24}

Process Analytical Technology (PAT), continuous manufacturing and real-time monitoring are also contributing to the transition toward more proactive quality management. PAT-based technologies, including near-infrared and Raman spectroscopy, can support real-time process assessment, while continuous

manufacturing can integrate process monitoring and control throughout production.^{22,23}

Another important trend is the development of **quality management maturity**, in which organizations move beyond minimum compliance toward stronger quality culture, proactive risk management, data-driven decision-making, knowledge management and continual improvement.^{24,25}

Table 6: Emerging Trends in Pharmaceutical Quality Assurance

Trend	Application in QA	Expected contribution
Quality by Design	Product/process development	Robust product and process
QRM	Risk identification and control	Risk-based decisions
PAT	Real-time monitoring	Process understanding
Continuous manufacturing	Integrated manufacturing	Improved control and flexibility
AI/ML	Prediction and anomaly detection	Data-driven QA
Electronic QMS	Quality workflows	Traceability and efficiency
Electronic batch records	Manufacturing documentation	Improved data integrity
Advanced analytics	Trend detection	Early identification of problems
Digital twins	Process simulation	Predictive process understanding
QMM	Quality-system maturity	Continual improvement
Lifecycle management	Post-approval improvement	Controlled change

Overall, the emerging direction of pharmaceutical quality assurance is toward an integrated system combining **scientific understanding, quality risk management, real-time monitoring, digital technologies, reliable data and continual improvement**. Successful implementation will require appropriate validation, data governance, cyber security, personnel competency and regulatory oversight.^{6,12,15,18,19,22–25}

3.23. Major Challenges

Despite substantial progress, pharmaceutical QA continues to face several challenges.

3.23.1. Increasing manufacturing complexity

Biologics, advanced therapies, combination products and complex formulations create additional quality challenges.

3.23.2. Global supply chains

Multiple suppliers and contract organizations can increase variability and complicate quality oversight.

3.23.3. Data integrity

The transition from paper-based to electronic systems creates additional requirements for governance, validation and cyber security.

3.23.4. Regulatory complexity

International manufacturers must manage different national and regional regulatory requirements.

3.23.5. Technology adoption

Advanced technologies require investment, specialized expertise and appropriate validation.

3.23.6. Quality culture

A documented quality system may be ineffective if organizational behavior does not support quality objectives.

3.23.7. AI governance

AI-based systems introduce new questions concerning validation, transparency, model drift, data provenance and accountability.

3.24. Future Perspectives



The future pharmaceutical QA environment is likely to become increasingly:

- Risk-based
- Lifecycle-oriented
- Data-driven
- Automated
- Predictive
- Digitally integrated
- Patient-focused

The integration of QbD, QRM, PAT, continuous manufacturing, AI/ML and digital quality systems could facilitate earlier identification of quality risks and greater process understanding.

Nevertheless, technological advancement should be accompanied by appropriate validation, data governance, cybersecurity, personnel training and regulatory oversight.

The future QA model can therefore be conceptualized as:

Scientific understanding + Risk management + Quality culture + Reliable data + Advanced technology + Continual improvement

CONCLUSION

Pharmaceutical quality assurance has evolved from a predominantly inspection- and testing-based activity into an integrated lifecycle-based quality-management discipline. GMP remains the foundation of pharmaceutical manufacturing, while pharmaceutical quality systems, quality risk management, validation, CAPA, change control, supplier management, documentation and data integrity provide the operational framework for maintaining consistent product quality.

Quality by Design has strengthened the scientific basis of pharmaceutical development by encouraging systematic identification of critical quality attributes, material attributes and process parameters. PAT and continuous manufacturing are facilitating greater real-time process understanding, while digitalization and AI/ML are creating new opportunities for predictive and data-driven quality management.

At the same time, these developments create new challenges related to data integrity, computerized-system validation, cyber security, model governance and regulatory oversight. The emerging concept of quality management maturity further emphasizes that pharmaceutical organizations should not limit their objective to minimum compliance but should develop robust systems capable of continual improvement and reliable performance.

Ultimately, effective pharmaceutical QA requires the coordinated integration of people, processes, technology, scientific knowledge, risk management and regulatory expectations. A mature and proactive quality system is essential not only for regulatory compliance but also for ensuring that patients consistently receive pharmaceutical products of appropriate quality, safety and therapeutic performance.

Acknowledgement

Not Applicable

Conflict of Interest

The author declares that there is no conflict of interest regarding the publication of this review article.

REFERENCES

1. World Health Organization. Quality assurance of pharmaceuticals: a compendium of guidelines and related materials. 10th ed. Vol. 1. Good practices and related regulatory guidance. Geneva: World Health Organization; 2024.
2. World Health Organization. Quality assurance of pharmaceuticals: a compendium of guidelines and related materials. 10th ed. Vol. 2. Good manufacturing practices and inspection. Geneva: World Health Organization; 2024.
3. Nunavath RS, Singh MT, Jain A, Chakma M, Arivuselvam R, Azeeze MSTA. Quality by Design in Pharmaceuticals: A Review of its Impact on Regulatory Compliance and Product Quality. *Drug Res (Stuttg)*. 2024;74 (1):18-23. doi:10.1055/a-2185-4916.
4. Simões A, Veiga F, Vitorino C. Question-based review for pharmaceutical development: An enhanced quality approach. *Eur J Pharm Biopharm*.



- 2024;195:114174. doi:10.1016/j.ejpb.2023.114174.
5. Hassen HK, Mekasha YT, Tegegne AA, Ozalp Y. A narrative review on problems in product quality, regulatory system constraints, and the concept of quality by design as a solution for quality assurance of African medicines. *Front Med.* 2024;11:1472495. doi:10.3389/fmed.2024.1472495.
6. International Council for Harmonisation. Quality guidelines [Internet]. Geneva: ICH; [cited 2026 Oct 14]. Available from: <https://www.ich.org/page/quality-guidelines>.
7. World Health Organization. WHO Expert Committee on Specifications for Pharmaceutical Preparations: 57th report. WHO Technical Report Series 1052. Geneva: World Health Organization; 2024.
8. World Health Organization. WHO good manufacturing practices for pharmaceutical products: main principles. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations: fortieth report. Geneva: World Health Organization; 2014. WHO Technical Report Series No. 986, Annex 2.
9. International Council for Harmonisation. ICH Q10: pharmaceutical quality system. Geneva: ICH; 2008.
10. International Council for Harmonisation. ICH Q9 (R1): Quality Risk Management. Geneva: ICH; 2021.
11. International Council for Harmonisation. ICH Q8 (R2): pharmaceutical development. Geneva: ICH; 2009.
12. Suriyaamporn P, et al. The Artificial Intelligence-Powered New Era in Pharmaceutical Research and Development: A Review. *AAPS PharmSciTech.* 2024;25 (6):188. doi:10.1208/s12249-024-02901-y.
13. US Food and Drug Administration. Process validation: general principles and practices. Guidance for Industry. Silver Spring (MD): FDA; 2011.
14. Pedro F, Veiga F, Mascarenhas-Melo F. Impact of GAMP 5, data integrity and QbD on quality assurance in the pharmaceutical industry: How obvious is it? *Drug Discov Today.* 2023;28 (11):103759. doi:10.1016/j.drudis.2023.103759.
15. Charoo NA, Khan MA, Rahman Z. Data integrity issues in pharmaceutical industry: Common observations, challenges and mitigation strategies. *Int J Pharm.* 2023;631:122503. doi:10.1016/j.ijpharm.2022.122503.
16. US Food and Drug Administration. Data integrity and compliance with drug CGMP: questions and answers. Guidance for Industry. Silver Spring (MD): FDA; 2018.
17. International Council for Harmonisation. ICH Q12: technical and regulatory considerations for pharmaceutical product lifecycle management. Geneva: ICH; 2019.
18. US Food and Drug Administration. CDER Quality Management Maturity [Internet]. Silver Spring (MD): FDA; [cited 2026 Oct 14]. Available from: <https://www.fda.gov/drugs/pharmaceutical-quality-resources/cder-quality-management-maturity>.
19. US Food and Drug Administration. Report on the State of Pharmaceutical Quality: FY2025 [Internet]. Silver Spring (MD): FDA; 2026 [cited 2026 Oct 14]. Available from: <https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/report-state-pharmaceutical-quality>.
20. World Health Organization. WHO good practices for pharmaceutical quality control laboratories. WHO Technical Report Series 1052, Annex 4. Geneva: World Health Organization; 2024.
21. International Council for Harmonisation. ICH Q14: analytical procedure development. Geneva: ICH; 2023.
22. Londhe SB, Kumar S, Agrawal AK, De Beer T, Kumar A, Kumar D. Continuous manufacturing in pharmaceuticals: an integrated approach with NIR and Raman as PAT tools. *Int J Pharm.* 2026;689:126478. doi:10.1016/j.ijpharm.2025.126478.



23. International Council for Harmonisation. ICH Q13: continuous manufacturing of drug substances and drug products. Geneva: ICH; 2022.
24. Huanbutta K, Burapapadh K, Kraisit P, Sriamornsak P, Ganokratanaa T, Suwanpitak K, et al. Artificial intelligence-driven pharmaceutical industry: A paradigm shift in drug discovery, formulation development, manufacturing, quality control, and post-market surveillance. *Eur J Pharm Sci.* 2024;203:106938. doi:10.1016/j.ejps.2024.106938.
25. Alosert H, Savery J, Rheaume J, Cheeks M, Turner R, Spencer C, et al. Data integrity within the biopharmaceutical sector in the era of Industry 4.0. *Biotechnol J.* 2022;17 (6):e2100609. doi:10.1002/biot.202100609.

HOW TO CITE: Santosh Kumar, Kusum Bala, Pharmaceutical Quality Assurance: Principles, Regulatory Framework, Current Practices and Emerging Trends – A Review, *Int. J. of Pharm. Sci.*, 2026, Vol 4, Issue 10, 4526-4539. <https://doi.org/10.5281/zenodo.23727721>

